FASN and breast carcinoma: Fasnall, a selective FASN inhibitor, reduced the proliferation of breast cancer cells and modulated the lipidomic profile of these cells by increasing ceramide levels due to malonyl-CoA accumulation and consequent CPT-1 inhibition [74].